"Our mission is to cure Central Nervous System (CNS) diseases with ethical next generation Regenerative Medicine solutions, fundamentally improving the quality of life for patients and helping to reduce overall healthcare costs."
The earliest life on Earth started over three billion years ago. To survive in most ecosystems, life started to adapt to challenges and thrive in a wide range of conditions. The Axolotl salamander is an animal capable of repairing and regenerating its central nervous system as well as its vital organs. Unlike the Axolotl, humans have limited regenerative powers: we are left with scars, diminished mobility, and weakened function.
Over 17 years ago, inventor Jan-Eric Ahlfors began work to unlock the mechanism that underpins the Axolotl's regeneration. His discoveries led to the development of regenerative implants and to unravelling direct cell reprogramming. He was the first to replicate in vitro the method of direct reprogramming for the production of autologous neural stem precursor cells. Today, directly reprogrammed neural precursor cells and regenerative implants are in development for regeneration of brain and spinal cord tissue.
Fortuna Fix was established in 2015 to bring these neuro-regenerative technologies to patients.
Fortuna Fix is a next-generation regenerative medicine company focused on neuronal repair and regeneration. Our goal is to establish regenerative medicine as a new paradigm of healthcare, bringing real solutions to conditions that cannot be cured by current therapeutic modalities. We are the first in the field of Regenerative Medicine to have developed ethical regenerative medicine solutions that can truly restore functionality in patients following neurotrauma and neurodegeneration.
Our patented technology portfolio includes autologous neural precursor cells produced by direct reprogramming (drNPC™) and regenerative implants Regeneration Matrix™ (RMx™) and fully Automated Manufacturing of the drNPC™ (patent pending) for rapid scale-up and production of the drNPC™.
OUR APPROACH TO CNS DISEASES
- our approach is customized to focus on the underlying pathologies associated with each condition
- our therapies are personalized to achieve functional integration and avoid issues of immunorejection
- our manufacturing is fully automated to ensure optimal production and large scale commercialization
Our lead development pipeline products (not approved for commercial use) are within the field of Neurodegeneration (Parkinson's Disease) and Neurotrauma (Spinal Cord Injury) and we are currently in the last stages of pre-clinical development with:
- Autologous drNPC-A9 Dopaminergic Neurons for Parkinson's Disease
- Autologous drNPC-O2 (oligogenic and motor neuron cells) for Spinal Cord Injury